19:00 CET | 18:00 GMT | 1:00 p.m. ET | 12:00 p.m. CT | 11:00 a.m. MT | 10:00 a.m. PT
Despite the significant disease burden, little has been published on the costs associated with a diagnosis of FSHD to the healthcare and payor systems. Most previous studies examining FSHD-associated costs were conducted outside of the United States. To better understand healthcare utilization and cost associated with FSHD in the United States, we conducted two studies: an analysis of a large dataset of medical claims from private insurers and Medicare; and analysis of data collected by the TrueCost FSHD survey. In this webinar, we will share what we have learned so far. Presented by June Kinoshita and Amanda Hill, FSHD Society.